7Kumar S,Krenacs L,Medeiros J,et al.Subcutaneous panniculitic like T-cell lymphoma is a tumor of cytotoxic T lymphocytes[J].Hum Pathol,1998,29 (12):379-403.
1Graig AJ, Cualing H, Thomas G, et al. Cytophagic histiocytic panniculitis-A syndrome associated with benign and malignant panniculitis: Case comparison and review of the literature. J Am Acad Dermatol, 1998,39(5): 721-736.
2Kumar S, Krenacs L, Medeiros J. Subcutaneous Panniculitis-like T cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol, 1998,29: 397-403.
3Perniciaro C, Zalla M J, White JW, et al. Subcutaneous T-cell lymphoma. Report of two additional cases and further observations. Arch Dermatol, 1993, 129(9): 1171-1776.
6Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma. Cancer, 2004,101 : 1404-1413.
7Weenig RH, Ng CS, Pemiciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol, 2001,23:206-215.
8Aghajanian C, Soignet S, Dizon DS, et al. A phase Ⅰ trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res, 2002,8:2505-2511.
9Goy A, Younes A, McLaughlin P, et al. Phase Ⅱ study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non- Hodgkin' s lymphoma. J Clin Oncol, 2005,23:667-675.
10Mai W, Meng H, Jin J, et al. Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol, 2006,77:445-447.
